| abstract |
(57) The present invention relates to a compound of the formula (I) And a therapeutic method including the same, a pharmaceutical composition containing the same, and an intermediate used in the production thereof. The compounds of the present invention selectively inhibit binding to α-1 a adrenergic receptors, receptors which are presumed to be involved in benign prostate hyperplasia. As such, the compounds have potential utility for use in treating such conditions. |